Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FID-007C
- Development stage
- Discontinued
- Lead developer
- Fulgent Pharma
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FID-007C is a discontinued nanoparticle formulation of paclitaxel developed by Fulgent Pharma for the treatment of lung cancer. The drug utilizes a proprietary nanoencapsulation technology involving a polyethyloxazoline (PEOX) polymer to deliver paclitaxel, a well-established microtubule-stabilizing agent. By binding to tubulin, paclitaxel inhibits the disassembly of microtubules, which arrests the cell cycle in the G2/M phase and induces apoptosis in rapidly dividing cancer cells. While the lead candidate in this platform, FID-007, continues to be evaluated in Phase 2 trials for head and neck squamous cell carcinoma (HNSCC), the FID-007C program specifically targeting lung cancer was discontinued by the developer.
- Other names
- paclitaxel nanoparticle PEOX lung cancer
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on FID-007C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FID-007C.